169 related articles for article (PubMed ID: 34675120)
21. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
[TBL] [Abstract][Full Text] [Related]
22. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
[TBL] [Abstract][Full Text] [Related]
23. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
25. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
[TBL] [Abstract][Full Text] [Related]
26. Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.
Reebye V; Querol Cano L; Lavery DN; Brooke GN; Powell SM; Chotai D; Walker MM; Whitaker HC; Wait R; Hurst HC; Bevan CL
Mol Endocrinol; 2012 Oct; 26(10):1694-706. PubMed ID: 22899854
[TBL] [Abstract][Full Text] [Related]
27. Hsp90: still a viable target in prostate cancer.
Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
[TBL] [Abstract][Full Text] [Related]
28. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
29. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
[TBL] [Abstract][Full Text] [Related]
30. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Rice MA; Kumar V; Tailor D; Garcia-Marques FJ; Hsu EC; Liu S; Bermudez A; Kanchustambham V; Shankar V; Inde Z; Alabi BR; Muruganantham A; Shen M; Pandrala M; Nolley R; Aslan M; Ghoochani A; Agarwal A; Buckup M; Kumar M; Going CC; Peehl DM; Dixon SJ; Zare RN; Brooks JD; Pitteri SJ; Malhotra SV; Stoyanova T
Cell Rep Med; 2022 Feb; 3(2):100502. PubMed ID: 35243415
[TBL] [Abstract][Full Text] [Related]
31. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression.
Akalin A; Elmore LW; Forsythe HL; Amaker BA; McCollum ED; Nelson PS; Ware JL; Holt SE
Cancer Res; 2001 Jun; 61(12):4791-6. PubMed ID: 11406554
[TBL] [Abstract][Full Text] [Related]
32. Heat shock protein 90 is associated with hyperplasia and neoplastic transformation of canine prostatic epithelial cells.
Palmieri C; Mancini M; Benazzi C; Della Salda L
J Comp Pathol; 2014 May; 150(4):393-8. PubMed ID: 24679854
[TBL] [Abstract][Full Text] [Related]
33. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
34. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
35. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.
Hoang AT; Huang J; Rudra-Ganguly N; Zheng J; Powell WC; Rabindran SK; Wu C; Roy-Burman P
Am J Pathol; 2000 Mar; 156(3):857-64. PubMed ID: 10702402
[TBL] [Abstract][Full Text] [Related]
36. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
37. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor.
Harashima K; Akimoto T; Nonaka T; Tsuzuki K; Mitsuhashi N; Nakano T
Int J Radiat Biol; 2005 Jan; 81(1):63-76. PubMed ID: 15962764
[TBL] [Abstract][Full Text] [Related]
38. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90.
Aalinkeel R; Bindukumar B; Reynolds JL; Sykes DE; Mahajan SD; Chadha KC; Schwartz SA
Prostate; 2008 Dec; 68(16):1773-89. PubMed ID: 18726985
[TBL] [Abstract][Full Text] [Related]
39. Hsp90 as a therapeutic target in prostate cancer.
Solit DB; Scher HI; Rosen N
Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
[TBL] [Abstract][Full Text] [Related]
40. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]